NewLink Genetics Corp (NASDAQ:NLNK) shares saw strong trading volume on Wednesday . 2,266,720 shares were traded during trading, an increase of 553% from the previous session’s volume of 347,006 shares.The stock last traded at $1.81 and had previously closed at $1.60.
Several equities research analysts recently weighed in on the company. Zacks Investment Research raised NewLink Genetics from a “hold” rating to a “strong-buy” rating and set a $2.50 price target for the company in a report on Wednesday, November 7th. Bank of America decreased their price target on NewLink Genetics from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Friday, November 2nd. Finally, ValuEngine raised NewLink Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. NewLink Genetics presently has an average rating of “Hold” and an average target price of $4.75.
The firm has a market capitalization of $68.86 million, a price-to-earnings ratio of -0.71 and a beta of 1.89.
NewLink Genetics Company Profile (NASDAQ:NLNK)
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.
Read More: Dividend Achievers
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.